Johnson Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johnson Thomas has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Daland R. Juberg
Human Health Science Policy, Corteva Agrisciences, Indianapolis, IN, USA.
1 shared publication Jay I. Goodman
‡ Department of Pharmacology & Toxicology, Michigan State University, East Lansing, Michigan, 48824
1 shared publicationJerrold M. Ward
§ 10513 Wayridge Drive, Montgomery Village, Maryland, 20886
1 shared publicationJoseph K. Haseman
† JK Haseman Consulting, 1054 Tacketts Pond Drive, Raleigh, North Carolina, 27614
1 shared publicationPamela J. Spencer
Toxicology & Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan 48674
1 shared publication- Rod Aaron Herman
Regulatory and Stewardship, Corteva Agriscience, Indianapolis, Indiana, USA
1 shared publication
Latest Publications
- Open Access
- 1 February 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 92, 220-225
No treatment-related effects with aryloxyalkanoate dioxygenase-12 in three 28-day mouse toxicity studies
- 1 February 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 92, 220-225
Open AccessNo treatment-related effects with aryloxyalkanoate dioxygenase-12 in three 28-day mouse toxicity studies
- Open Access
- 22 May 2007
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 99 (1) , 3-19
A Review of Large Granular Lymphocytic Leukemia in Fischer 344 Rats as an Initial Step Toward Evaluating the Implication of the Endpoint to Human Cancer Risk Assessment
Large granular lymphocyte leukemia (LGLL) is a common fatal disease in aging F344 rats. The current understanding of rat LGLL and a search for mechanistic data/correlations to human leukemia were examined with the goal of improving evaluation of the LGLL endpoint in cancer bioassays as it relates to human cancer risk assessments. The exact cell of origin of the F344 rat LGLL is not fully resolved, although natural killer (NK) cell characteristics were demonstrated in most, if not all cases. Similarities between rat LGLL and a rare human NK-LGLL exist, invalidating claims of no human counterpart, although the underlying etiopathogenesis may be different. There is insufficient data to establish a mode of action of chemical-induced rat LGLL. Evaluation of the National Toxicology Program database revealed only 34 substances (out of over 500 studied) that were possibly associated with increased incidences of LGLL. Of these, only five produced definitive LGLL effects in both sexes; the remaining 29 produced single sex responses and/or only “equivocal” associations with LGLL. Trends of increasing background/variability in LGLL incidence and its modulation by extraneous factors (e.g., corn oil gavage) are key confounders in interpretation. Given that LGLL is a common tumor in control F344 rats, interpretations of bioassays can be improved by increasing the statistical stringency (e.g., p < 0.01 over traditional p < 0.05), as an indicator of possible carcinogenic effects, but that alone would be insufficient evidence for declaring treatment-related increases. Thus, it was concluded that the evaluation of possible chemically related increases in rat LGLL utilize a “weight-of-evidence” approach.
- 22 May 2007
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 99 (1) , 3-19
Open AccessA Review of Large Granular Lymphocytic Leukemia in Fischer 344 Rats as an Initial Step Toward Evaluating the Implication of the Endpoint to Human Cancer Risk Assessment
Large granular lymphocyte leukemia (LGLL) is a common fatal disease in aging F344 rats. The current understanding of rat LGLL and a search for mechanistic data/correlations to human leukemia were examined with the goal of improving evaluation of the LGLL endpoint in cancer bioassays as it relates to human cancer risk assessments. The exact cell of origin of the F344 rat LGLL is not fully resolved, although natural killer (NK) cell characteristics were demonstrated in most, if not all cases. Similarities between rat LGLL and a rare human NK-LGLL exist, invalidating claims of no human counterpart, although the underlying etiopathogenesis may be different. There is insufficient data to establish a mode of action of chemical-induced rat LGLL. Evaluation of the National Toxicology Program database revealed only 34 substances (out of over 500 studied) that were possibly associated with increased incidences of LGLL. Of these, only five produced definitive LGLL effects in both sexes; the remaining 29 produced single sex responses and/or only “equivocal” associations with LGLL. Trends of increasing background/variability in LGLL incidence and its modulation by extraneous factors (e.g., corn oil gavage) are key confounders in interpretation. Given that LGLL is a common tumor in control F344 rats, interpretations of bioassays can be improved by increasing the statistical stringency (e.g., p < 0.01 over traditional p < 0.05), as an indicator of possible carcinogenic effects, but that alone would be insufficient evidence for declaring treatment-related increases. Thus, it was concluded that the evaluation of possible chemically related increases in rat LGLL utilize a “weight-of-evidence” approach.